ARQT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ARQT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Gross Margin % is calculated as gross profit divided by its revenue. Arcutis Biotherapeutics's Gross Profit for the three months ended in Dec. 2024 was $64.5 Mil. Arcutis Biotherapeutics's Revenue for the three months ended in Dec. 2024 was $71.4 Mil. Therefore, Arcutis Biotherapeutics's Gross Margin % for the quarter that ended in Dec. 2024 was 90.32%.
The historical rank and industry rank for Arcutis Biotherapeutics's Gross Margin % or its related term are showing as below:
During the past 8 years, the highest Gross Margin % of Arcutis Biotherapeutics was 91.63%. The lowest was 79.54%. And the median was 90.27%.
Arcutis Biotherapeutics had a gross margin of 90.32% for the quarter that ended in Dec. 2024 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Arcutis Biotherapeutics was 0.00% per year.
The historical data trend for Arcutis Biotherapeutics's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arcutis Biotherapeutics Annual Data | |||||||||||||||||
Trend | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||
Gross Margin % | Get a 7-Day Free Trial | - | - | 79.54 | 91.63 | 90.27 |
Arcutis Biotherapeutics Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Gross Margin % | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
83.39 | 93.43 | 88.77 | 87.70 | 90.32 |
For the Biotechnology subindustry, Arcutis Biotherapeutics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Arcutis Biotherapeutics's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Arcutis Biotherapeutics's Gross Margin % falls into.
Gross Margin is the percentage of Gross Profit out of sales or Revenue.
Arcutis Biotherapeutics's Gross Margin for the fiscal year that ended in Dec. 2024 is calculated as
Gross Margin % (A: Dec. 2024 ) | = | Gross Profit (A: Dec. 2024 ) | / | Revenue (A: Dec. 2024 ) |
= | 177.4 | / | 196.542 | |
= | (Revenue - Cost of Goods Sold) | / | Revenue | |
= | (196.542 - 19.128) | / | 196.542 | |
= | 90.27 % |
Arcutis Biotherapeutics's Gross Margin for the quarter that ended in Dec. 2024 is calculated as
Gross Margin % (Q: Dec. 2024 ) | = | Gross Profit (Q: Dec. 2024 ) | / | Revenue (Q: Dec. 2024 ) |
= | 64.5 | / | 71.36 | |
= | (Revenue - Cost of Goods Sold) | / | Revenue | |
= | (71.36 - 6.905) | / | 71.36 | |
= | 90.32 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Arcutis Biotherapeutics (NAS:ARQT) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Arcutis Biotherapeutics had a gross margin of 90.32% for the quarter that ended in Dec. 2024 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Thank you for viewing the detailed overview of Arcutis Biotherapeutics's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Todd Franklin Watanabe | director, officer: President and CEO | C/O ARCUTIS BIOTHERAPEUTICS, INC., 2945 TOWNSGATE ROAD, SUITE 110, WESTLAKE VILLAGE CA 91361 |
Patrick Burnett | officer: See Remarks | C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380 |
Howard G. Welgus | director | C/O ARCUTIS BIOTHERAPEUTICS, INC., 2945 TOWNSGATE ROAD, SUITE 110, WESTLAKE VILLAGE CA 91361 |
Masaru Matsuda | officer: SVP and General Counsel | 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121 |
Larry Todd Edwards | officer: Chief Commercial Officer | C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE CA 91361 |
Terrie Curran | director | C/O MYOVANT SCIENCES INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018 |
Matthew Richard Moore | officer: SVP and Chief Business Officer | C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE CA 91361 |
Patrick J Heron | director, 10 percent owner | 550 HAMILTON AVE., SUITE 100, PALO ALTO CA 94301 |
Frazier Life Sciences Viii, L.p. | 10 percent owner | 601 UNION STREET, SUITE 3200, SEATTLE WA 98101 |
Scott L Burrows | officer: Chief Financial Officer | C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE CA 91361 |
Patricia A. Turney | officer: Senior VP, Manufacturing | C/O ARCUTIS BIOTHERAPEUTICS, INC., 2945 TOWNSGATE ROAD, SUITE 110, WESTLAKE VILLAGE CA 91361 |
David W Osborne | officer: Chief Technical Officer | |
Kenneth A. Lock | officer: Chief Commercial Officer | C/O ARCUTIS BIOTHERAPEUTICS, INC., 2945 TOWNSGATE ROAD, SUITE 110, WESTLAKE VILLAGE CA 91361 |
Neha Krishnamohan | director | 12707 HIGH BLUFF DRIVE, SAN DIEGO CA 92130 |
Orbimed Advisors Llc | director, 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
From GuruFocus
By Marketwired • 01-12-2025
By GuruFocus News • 02-05-2025
By GuruFocus News • 03-07-2025
By GuruFocus News • 02-04-2025
By GuruFocus News • 02-26-2025
By GuruFocus News • 02-25-2025
By Marketwired • 02-18-2025
By GuruFocus News • 02-26-2025
By Marketwired • 01-27-2025
By GuruFocus News • 02-05-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.